Total Payments
$1.9M
2024 Payments
$59,973
Companies
60
Transactions
2,670
Medicare Patients
3,950
Medicare Billing
$4.1M
Payment Breakdown by Category
Other$1.3M (68.2%)
Consulting$356,305 (18.4%)
Travel$210,605 (10.9%)
Food & Beverage$47,660 (2.5%)
Research$1,142 (0.1%)
Education$762.34 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.3M | 598 | 64.9% |
| Consulting Fee | $356,305 | 127 | 18.4% |
| Travel and Lodging | $210,605 | 648 | 10.9% |
| Honoraria | $64,738 | 34 | 3.3% |
| Food and Beverage | $47,660 | 1,237 | 2.5% |
| Unspecified | $1,142 | 4 | 0.1% |
| Education | $762.34 | 19 | 0.0% |
| Grant | $129.40 | 3 | 0.0% |
Payments by Type
General
$1.9M
2,666 transactions
Research
$1,142
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $382,154 | 453 | $0 (2022) |
| Amgen Inc. | $276,476 | 358 | $0 (2023) |
| Lilly USA, LLC | $264,955 | 357 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $258,729 | 293 | $0 (2024) |
| ABBVIE INC. | $251,330 | 371 | $0 (2024) |
| Biohaven Pharmaceuticals, Inc. | $77,600 | 80 | $0 (2021) |
| Ipsen Innovation | $60,106 | 18 | $0 (2024) |
| Lundbeck LLC | $58,133 | 78 | $0 (2024) |
| Promius Pharma LLC | $50,810 | 75 | $0 (2019) |
| IMPEL PHARMACEUTICALS INC. | $50,671 | 36 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $59,973 | 79 | Ipsen Innovation ($42,014) |
| 2023 | $125,134 | 175 | AbbVie Inc. ($65,761) |
| 2022 | $290,425 | 318 | ABBVIE INC. ($105,941) |
| 2021 | $371,275 | 387 | Allergan, Inc. ($81,768) |
| 2020 | $288,478 | 338 | Allergan, Inc. ($96,493) |
| 2019 | $442,702 | 709 | Teva Pharmaceuticals USA, Inc. ($125,347) |
| 2018 | $248,423 | 423 | Amgen Inc. ($98,926) |
| 2017 | $113,958 | 241 | Allergan Inc. ($44,813) |
All Payment Transactions
2,670 individual payment records from CMS Open Payments — Page 1 of 107
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | ABBVIE INC. | BOTOX (Biological) | Travel and Lodging | In-kind items and services | $409.15 | General |
| Category: NEUROSCIENCE | ||||||
| 11/26/2024 | ABBVIE INC. | BOTOX (Biological) | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| Category: FACIAL AESTHETICS | ||||||
| 11/20/2024 | Axsome Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,375.00 | General |
| 11/20/2024 | ABBVIE INC. | BOTOX (Biological) | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| Category: FACIAL AESTHETICS | ||||||
| 11/19/2024 | Lundbeck LLC | VYEPTI (Biological) | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| Category: NEUROLOGY | ||||||
| 11/16/2024 | Tonix Medicines, Inc. | ZEMBRACE SYMTOUCH (Drug) | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: NEUROLOGY | ||||||
| 11/15/2024 | Tonix Medicines, Inc. | ZEMBRACE SYMTOUCH (Drug) | Food and Beverage | In-kind items and services | $83.20 | General |
| Category: NEUROLOGY | ||||||
| 11/15/2024 | Ipsen Biopharmaceuticals, Inc | Dysport (Drug) | Food and Beverage | In-kind items and services | $39.86 | General |
| Category: Neurology | ||||||
| 11/15/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $39.45 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/14/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $130.86 | General |
| Category: FACIAL AESTHETICS | ||||||
| 11/14/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $97.55 | General |
| Category: NEUROSCIENCE | ||||||
| 11/14/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $95.46 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/12/2024 | Genentech USA, Inc. | Ocrevus Zunovo (Biological) | Food and Beverage | In-kind items and services | $20.85 | General |
| Category: Immunology | ||||||
| 11/11/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| 11/01/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $28.88 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 10/31/2024 | Ipsen Innovation | — | Consulting Fee | Cash or cash equivalent | $17,360.00 | General |
| 10/31/2024 | Ipsen Innovation | — | Travel and Lodging | In-kind items and services | $160.00 | General |
| 10/31/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $19.73 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 10/30/2024 | Lundbeck LLC | VYEPTI (Biological) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: NEUROLOGY | ||||||
| 10/30/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $32.82 | General |
| Category: NEUROSCIENCE | ||||||
| 10/29/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $14.88 | General |
| Category: Neuroscience | ||||||
| 10/23/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $110.56 | General |
| Category: NEUROSCIENCE | ||||||
| 10/23/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Travel and Lodging | In-kind items and services | $4.35 | General |
| Category: NEUROSCIENCE | ||||||
| 10/17/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $33.46 | General |
| Category: NEUROSCIENCE | ||||||
| 10/10/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: PAIN | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $571.00 | 2 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $571.00 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 1,085 | 213,488 | $3.1M | $1.2M |
| 2022 | 14 | 926 | 168,799 | $2.3M | $963,625 |
| 2021 | 14 | 945 | 174,200 | $2.3M | $998,954 |
| 2020 | 15 | 994 | 170,772 | $2.2M | $936,382 |
Total Patients
3,950
Total Services
727,259
Medicare Billing
$4.1M
Procedure Codes
60
All Medicare Procedures & Services
60 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 322 | 211,665 | $2.5M | $1.0M | 40.9% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 236 | 652 | $228,200 | $82,117 | 36.0% |
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | Office | 2023 | 49 | 149 | $83,364 | $22,022 | 26.4% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Office | 2023 | 88 | 245 | $43,843 | $17,297 | 39.5% |
| 64644 | Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | Office | 2023 | 31 | 84 | $31,592 | $12,665 | 40.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 106 | 125 | $33,375 | $12,225 | 36.6% |
| 64612 | Injection of chemical for paralysis of nerve muscles on side of face | Office | 2023 | 23 | 61 | $37,820 | $10,790 | 28.5% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 20 | 168 | $21,929 | $8,449 | 38.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 53 | 57 | $21,318 | $7,958 | 37.3% |
| 64400 | Injection of anesthetic agent and/or steroid into face nerve | Office | 2023 | 14 | 30 | $14,725 | $4,157 | 28.2% |
| 64642 | Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | Office | 2023 | 13 | 26 | $8,257 | $3,154 | 38.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 18 | 18 | $8,190 | $3,053 | 37.3% |
| 64643 | Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, each additional extremity | Office | 2023 | 16 | 37 | $7,165 | $2,887 | 40.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 34 | 42 | $7,938 | $2,861 | 36.0% |
| 64405 | Injection of anesthetic agent and/or steroid into upper neck and back of head nerve | Office | 2023 | 14 | 24 | $8,924 | $1,374 | 15.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 21 | 25 | $1,250 | $283.36 | 22.7% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2023 | 27 | 80 | $640.00 | $34.43 | 5.4% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 273 | 167,225 | $1.9M | $812,637 | 43.0% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2022 | 193 | 508 | $177,800 | $60,530 | 34.0% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 50 | 320 | $27,815 | $16,351 | 58.8% |
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | Office | 2022 | 46 | 112 | $53,699 | $15,583 | 29.0% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Office | 2022 | 77 | 179 | $27,137 | $13,277 | 48.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 88 | 111 | $23,475 | $10,839 | 46.2% |
| 64644 | Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | Office | 2022 | 26 | 65 | $17,622 | $9,814 | 55.7% |
| 64612 | Injection of chemical for paralysis of nerve muscles on side of face | Office | 2022 | 21 | 54 | $32,860 | $9,242 | 28.1% |
About Dr. Jack Schim, M.D
Dr. Jack Schim, M.D is a Neurology healthcare provider based in Carlsbad, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1346276375.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jack Schim, M.D has received a total of $1.9M in payments from pharmaceutical and medical device companies, with $59,973 received in 2024. These payments were reported across 2,670 transactions from 60 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.3M).
As a Medicare-enrolled provider, Schim has provided services to 3,950 Medicare beneficiaries, totaling 727,259 services with total Medicare billing of $4.1M. Data is available for 4 years (2020–2023), covering 60 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Carlsbad, CA
- Active Since 06/23/2006
- Last Updated 09/11/2025
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1346276375
Products in Payments
- BOTOX (Biological) $288,367
- Aimovig (Biological) $246,870
- UBRELVY (Drug) $188,009
- EMGALITY (Drug) $164,479
- AJOVY (Drug) $162,168
- NURTEC ODT (Drug) $107,241
- BOTOX (Drug) $95,192
- AJOVY (Biological) $88,450
- VYEPTI (Biological) $63,245
- REYVOW (Drug) $59,275
- Trudhesa (Drug) $50,671
- Zembrace (Drug) $45,765
- QULIPTA (Drug) $27,866
- AMG334A_AIMOVIG_NEUROSCIENCE (Biological) $24,997
- TREXIMET (Drug) $23,731
- Dysport (Drug) $21,573
- QUDEXY XR Topiramate Extended Release Capsules (Drug) $17,316
- Gralise (Drug) $14,575
- TOSYMRA (Drug) $13,598
- AMG334A (Biological) $10,345
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Carlsbad
Dr. Brian Droker, Md, MD
Neurology — Payments: $365,185
Neurology $365,185
Dr. Anchi Wang, M.d, M.D
Neurology — Payments: $24,386
Neurology $24,386
Dr. Shreya Shah, M.d, M.D
Neurology — Payments: $21,100
Neurology $21,100
Dr. Irene Oh, M.d, M.D
Neurology — Payments: $18,057
Neurology $18,057
Aman Savani, Md, MD
Neurology — Payments: $12,321
Neurology $12,321
William Farnsworth, M.d, M.D
Neurology — Payments: $7,777
Neurology $7,777